Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00906399
Registration number
NCT00906399
Ethics application status
Date submitted
20/05/2009
Date registered
21/05/2009
Date last updated
19/09/2014
Titles & IDs
Public title
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Query!
Secondary ID [1]
0
0
2008-006333-27
Query!
Secondary ID [2]
0
0
105MS301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ADVANCE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BIIB017 (peginterferon beta-1a)
Treatment: Drugs - Placebo
Placebo Comparator: Placebo - Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
Experimental: Peginterferon Beta-1a Q2W - 125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
Experimental: Peginterferon Beta-1a Q4W - 125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
Treatment: Drugs: BIIB017 (peginterferon beta-1a)
Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
Treatment: Drugs: Placebo
Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annualized Relapse Rate (ARR) at 1 Year
Query!
Assessment method [1]
0
0
A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by an independent neurology evaluation committee (INEC) are included in the analysis. Data after participants switched to alternative multiple sclerosis (MS) medications are excluded. Data were analyzed using negative binomial regression, adjusted for baseline Expanded Disability Status Scale (EDSS) score (< 4 versus = 4), baseline age (< 40 versus = 40 years), and baseline relapse rate (number of relapses in 3 years prior to study entry divided by 3).
Query!
Timepoint [1]
0
0
1 Year
Query!
Secondary outcome [1]
0
0
Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year
Query!
Assessment method [1]
0
0
Number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans. Data observed after participants switched to alternative MS medications are excluded. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions.
Query!
Timepoint [1]
0
0
1 Year
Query!
Secondary outcome [2]
0
0
Proportion of Participants Relapsed at 1 Year
Query!
Assessment method [2]
0
0
A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by INEC were included in the analysis. Estimated proportion of participants relapsed is based on the Kaplan-Meier product limit method.
Query!
Timepoint [2]
0
0
Year 1
Query!
Secondary outcome [3]
0
0
Estimated Proportion of Participants With Sustained Disability Progression at 1 Year
Query!
Assessment method [3]
0
0
Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from baseline EDSS = 1.0 that is sustained for 12 weeks, or at least a 1.5 point increase on the EDSS from baseline EDSS = 0 that is sustained for 12 weeks. The EDSS measures the disability status of people with MS on a scale that ranges from 0 to 10. The range of main categories include 0 (normal neurologic examination), to 5 (ambulatory without aid or rest for 200 meters/disability severe enough to impair full daily activities), to 10 (death due to MS). Estimated proportion of participants with progression based on the Kaplan-Meier product limit method.
Query!
Timepoint [3]
0
0
1 Year
Query!
Eligibility
Key inclusion criteria
Key
- Must have a confirmed diagnosis of relapsing multiple sclerosis (RMS), as defined by
McDonald criteria 1 through 4 (Polman, 2005)
- Must have an EDSS score between 0.0 and 5.0.
- Must have experienced at least 2 relapses that have been medically documented within
the last 3 years with at least one occurring in the last 12 months
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Other chronic disease of immune system, malignancies, urologic, pulmonary,
gastrointestinal disease
- Pregnant or nursing women
- Prior treatment with interferon could not exceed 4 weeks and subjects must have
discontinued interferon treatment 6 months prior to Baseline
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1516
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Iowa
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
'Sint-Truiden
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Bruxelles
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Plovdiv
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Sofia
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
Chile
Query!
State/province [18]
0
0
Santiago
Query!
Country [19]
0
0
Colombia
Query!
State/province [19]
0
0
Atlantico
Query!
Country [20]
0
0
Colombia
Query!
State/province [20]
0
0
Cundinamarca
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Bogota
Query!
Country [22]
0
0
Croatia
Query!
State/province [22]
0
0
Osijek
Query!
Country [23]
0
0
Croatia
Query!
State/province [23]
0
0
Zagreb
Query!
Country [24]
0
0
Czech Republic
Query!
State/province [24]
0
0
Brno
Query!
Country [25]
0
0
Czech Republic
Query!
State/province [25]
0
0
Olomouc
Query!
Country [26]
0
0
Czech Republic
Query!
State/province [26]
0
0
Ostrava - Vitkovice
Query!
Country [27]
0
0
Czech Republic
Query!
State/province [27]
0
0
Ostrava-Poruba
Query!
Country [28]
0
0
Czech Republic
Query!
State/province [28]
0
0
Ostrava
Query!
Country [29]
0
0
Czech Republic
Query!
State/province [29]
0
0
Praha 2
Query!
Country [30]
0
0
Czech Republic
Query!
State/province [30]
0
0
Praha 5
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Teplice
Query!
Country [32]
0
0
Estonia
Query!
State/province [32]
0
0
Parnu
Query!
Country [33]
0
0
Estonia
Query!
State/province [33]
0
0
Tallinn
Query!
Country [34]
0
0
Estonia
Query!
State/province [34]
0
0
Tartu
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Amiens
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Clermont-Ferrand
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Lyon
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Marseille
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Nice
Query!
Country [40]
0
0
Georgia
Query!
State/province [40]
0
0
Tbilisi
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Bayreuth
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Berlin
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bochum
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Erbach
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Erlangen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Hamburg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Hannover
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Koln
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Leipzig
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Marburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Munchen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Munster
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Prien
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Ulm
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Westerstede
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Athens
Query!
Country [57]
0
0
Greece
Query!
State/province [57]
0
0
Thessaloniki
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Delhi
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Gujarat
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Karnataka
Query!
Country [61]
0
0
India
Query!
State/province [61]
0
0
Madhyr Pradesh
Query!
Country [62]
0
0
India
Query!
State/province [62]
0
0
Maharashtra
Query!
Country [63]
0
0
India
Query!
State/province [63]
0
0
Punjab
Query!
Country [64]
0
0
India
Query!
State/province [64]
0
0
Rajasthan
Query!
Country [65]
0
0
India
Query!
State/province [65]
0
0
Tamil Nadu
Query!
Country [66]
0
0
India
Query!
State/province [66]
0
0
West Bengal
Query!
Country [67]
0
0
India
Query!
State/province [67]
0
0
Bangalore
Query!
Country [68]
0
0
India
Query!
State/province [68]
0
0
Mangalore
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Navi Mumbai
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Nehru Nagar
Query!
Country [71]
0
0
Latvia
Query!
State/province [71]
0
0
Riga
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Aquas Calientes
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Chihuahua
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Mexico City
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Mexico DF
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Monterrey, Nuevo Leon
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
Tijuana, Baja California
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Breda
Query!
Country [79]
0
0
Netherlands
Query!
State/province [79]
0
0
Nieuwegein
Query!
Country [80]
0
0
New Zealand
Query!
State/province [80]
0
0
Auckland
Query!
Country [81]
0
0
New Zealand
Query!
State/province [81]
0
0
Christchurch
Query!
Country [82]
0
0
New Zealand
Query!
State/province [82]
0
0
Dunedin
Query!
Country [83]
0
0
Peru
Query!
State/province [83]
0
0
Lima
Query!
Country [84]
0
0
Peru
Query!
State/province [84]
0
0
San Isidro
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Bialystok
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Bydgoszcz
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Gdansk
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Katowice
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Konskie
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Krakow
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Lodz
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lublin
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Olsztyn
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Plewiska
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Poznan
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Szczecin
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Warsawa
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Wroclaw
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Zabrze
Query!
Country [100]
0
0
Romania
Query!
State/province [100]
0
0
Brasov
Query!
Country [101]
0
0
Romania
Query!
State/province [101]
0
0
Bucharest
Query!
Country [102]
0
0
Romania
Query!
State/province [102]
0
0
Campulung
Query!
Country [103]
0
0
Romania
Query!
State/province [103]
0
0
Iasi
Query!
Country [104]
0
0
Romania
Query!
State/province [104]
0
0
Sibiu
Query!
Country [105]
0
0
Romania
Query!
State/province [105]
0
0
Targu Mures
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Chelyabinsk
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Kaluga
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Kazan
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Krasnodar
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Kursk
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Moscow
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Novosibirsk
Query!
Country [113]
0
0
Russian Federation
Query!
State/province [113]
0
0
Perm
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Rostov-on-Don
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Smolensk
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
Tomsk
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Ufa
Query!
Country [118]
0
0
Serbia
Query!
State/province [118]
0
0
Belgrade
Query!
Country [119]
0
0
Serbia
Query!
State/province [119]
0
0
Kragujevac
Query!
Country [120]
0
0
Serbia
Query!
State/province [120]
0
0
Nis
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Cordoba
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Madrid
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Malaga
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Sevilla
Query!
Country [125]
0
0
Ukraine
Query!
State/province [125]
0
0
Chernivtsi
Query!
Country [126]
0
0
Ukraine
Query!
State/province [126]
0
0
Dnipropetrovsk
Query!
Country [127]
0
0
Ukraine
Query!
State/province [127]
0
0
Donetsk
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Kharkiv
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Kyiv
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Odesa
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Poltava
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Simferopol
Query!
Country [133]
0
0
Ukraine
Query!
State/province [133]
0
0
Ternopil
Query!
Country [134]
0
0
Ukraine
Query!
State/province [134]
0
0
Vinnytsya
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
London
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Nottingham
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Salford
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Biogen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in
reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis
(RMS) at 1 year. The secondary objectives of this study are to determine whether
peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the
total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance
imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the
progression of disability.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00906399
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Biogen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00906399
Download to PDF